Biosimilars in the U.S. have begun to fulfill their promise of generating savings for the healthcare system by reducing the cost of biologics. However, many studies and reports have highlighted issues within the current system that can lead to sub-optimal uptake of infused biosimilars and put the long-term sustainability of infused biosimilars at risk. Understanding these issues with case studies and examples is critical if biosimilars are to continue playing a crucial role in the overall health system.

This webinar is a follow on to the IQVIA Institute report by the same name and will discuss the dynamics of infused biosimilars to better understand key issues that may impact the biosimilars market in the U.S.

Potential discussion points:

• Current state of the use of infused biosimilars
• Challenges to long-term sustainability of infused biosimilars
• Overcoming challenges to long-term sustainability of infused biosimilars: Policy Needs Confirmed panelists to date:
• Neal Lambert, Senior Director, Pricing Strategy, U.S. Oncology Biosimilars at Pfizer
• Steven Lucio, Senior Principal at Vizient
• Jeff Patton, CEO at OneOncology
• Juliana Reed, Executive Director at Biosimilars Forum
• Scott Soefje, Director of Pharmacy Cancer Care and Assistant Professor of Pharmacy, Mayo Clinic Agenda
• Welcome: Murray Aitken, Executive Director, IQVIA Institute for Human Data Science
• Key Research Highlights
• Comments and discussion by panelists: Murray Aitken, Moderator
• Q&A
• Conclusion